retatrutide side effects clinical trials Results from trials? What side effects are reported

Knownwell expands hybrid care in Chicago

Retatrutide has generated significant and rapidly expanding research interest as the first tri-receptor incretin agonist to reach advanced pre-clinical and clinical investigation: Triple Receptor Mechanism: Research has characterised Retatrutides balanced activity across GLP-1R, GIPR, and GCGR, with studies documenting its receptor binding affinities, downstream signalling characteristics at each receptor, and the combined metabolic profile produced by tri-agonist co-stimulation confirming a pharmacological profile that is fundamentally broader than any dual or single-receptor compound

The trial also documented a reduction in WOMAC pain scores by up to 75.8%, improvements in non-HDL cholesterol, and reductions in systolic blood pressure

What is the protocol for reporting adverse reactions